“Various treatment options such as biologics and JAK inhibitors have emerged for ulcerative colitis, but the patients’ options are limited because the government does not allow switching between drugs. Especially as the number of young patients in their 20s and 30s and their life expectancy is both increasing, securing various treatment options for these patients has become the more important.”

Tae Oh Kim, Professor of Gastroenterology at Inje University Haeundae Paik Hospital explained so in a recent interview with Dailypharm regarding Korea’s ulcerative colitis treatment landscape.  

Ulcerative colitis is a chronic inflammatory growth disease of an unknown cause char